Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, followingsingle-dose administration by subcutaneous and intravenous routes in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 6, 2013, Pages 443-455

  Zhang, Xiaoping ^a   Georgy, Angela ^a   Rowell, Lucy ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Absolute bioavailability; Intravenous administration; Pharmacodynamics; Pharmacokinetics; Subcutaneous administration; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; TOCILIZUMAB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH ULCER; NAUSEA; NEUROLOGIC DISEASE; NEUTROPHIL COUNT; PHARMACODYNAMICS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUS HEADACHE; TONGUE DISEASE; TOOTH PAIN;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL AVAILABILITY; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; TIME FACTORS; YOUNG ADULT;

EID: 84878780747     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201819     Document Type: Article

References (25)

1. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005; 5: 1731-1740. CrossRef PubMed (Pubitemid 41116745)
2. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008; 67: 1516-1523. CrossRef PubMed
3. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008; 58: 2968-2980. CrossRef PubMed
4. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy vs. methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010; 69: 88-96. CrossRef PubMed
5. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371: 987-997. CrossRef PubMed (Pubitemid 351392039)
6. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011; 63: 609-621. CrossRef PubMed
7. RoACTEMRA® 20 mg/ml concentrate for solution for infusion [summary of product characteristics]. Welwyn Garden City, UK: Roche Registration Limited; January 2010.
8. ACTEMRA® for intravenous infusion [prescribing information]. Tokyo, Japan: Chugai Pharmaceutical Co., Ltd.; February 2009.
9. ACTEMRA® (tocilizumab) injection for intravenous infusion [prescribing information]. South San Francisco, CA: Genentech Inc.; April 2011.
10. U.S. Food and Drug Administration. FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Table A, Local Reaction to Injectable Product. Rockville, MD: FDA; September 2007.
11. Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010; 50: 754-766. CrossRef PubMed
12. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006; 11: 81-88. CrossRef PubMed (Pubitemid 43227856)
13. Tang L, Persky AM, Hochhaus G, Meibohm B. Pharmacokinetic aspects of biotechnology products. J Pharm Sci. 2004; 93: 2184-2204. CrossRef PubMed (Pubitemid 39129617)
14. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004; 93: 2645-2668. CrossRef PubMed (Pubitemid 39506617)
15. Zhuang Y, Xu Z, Frederick B, de Vries DE, Ford JA, Keen M, Doyle MK, Petty KJ, Davis HM, Zhou H. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther. 2012; 34: 77-90. CrossRef PubMed
16. Sutjandra L, Rodriguez RD, Doshi S, Ma M, Peterson MC, Jang GR, Chow AT, Pérez-Ruixo JJ. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011; 50: 793-807. CrossRef PubMed
17. Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011; 50: 215-227. CrossRef PubMed
18. Xu Z, Wang Q, Zhuang Y, Frederick B, Yan H, Bouman-Thio E, Marini JC, Keen M, Snead D, Davis HM, Zhou H. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol. 2010; 50: 276-284. CrossRef PubMed
19. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathological significances in increase in serum interleukin (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman's disease. Blood. 2008; 112: 2959-2964. CrossRef
20. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011; 89: 735-740. CrossRef PubMed
21. Yap SH, Moshage HJ, Hazenberg BP, Roelofs HM, Bijzet J, Limburg PC, Aarden LA, van Rijswijk MH. Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta. 1991; 1091: 405-408. CrossRef PubMed
22. Swaak AJ, van Rooyen A, Nieuwenhuis E, Aarden LA. Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol. 1988; 17: 469-474. CrossRef PubMed (Pubitemid 19068600)
23. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol. 1997; 24: 1477-1485. PubMed (Pubitemid 27320685)
24. Levi M, Charoin J, Frey N, Belor I. Jacquim P. A mechanistic target mediated drug disposition (TMDD) model is required to correctly estimate the bioavailability of a subcutaneous formulation of tocilizumab (TCZ), a monoclonal antibody with non-linear kinetics. Poster presented at: American Conference on Pharmacometrics; October 2009; Mashantucket, CT (http://2009.goacop.org/sites/ all/assets/webform/ACOP-October2009-final1.pdf).
25. Jørgensen JT, Rømsing J, Rasmussen M, Møller- Sonnergaard J, Vang L, Musaeus L. Pain assessment of subcutaneous injections. Ann Pharmacother. 1996; 30: 729-732. PubMed (Pubitemid 26243913)